Pipeline Report: April 2022 | Articles

Epcoritamab Elicits 63.1% ORR in Relapsed/Refractory Large B-cell Lymphoma

April 14th 2022

Epcoritamab was found to produce an encouraging overall response rate in patients with relapsed or refractory large B-cell lymphoma who previously received CAR T-cell therapy.

Neoadjuvant Chemoimmunotherapy Demonstrates Activity in Advanced Ovarian Cancer

April 13th 2022

The addition of durvalumab and tremelimumab to chemotherapy led to encouraging responses and a suitable safety profile as neoadjuvant therapy in patients with advanced ovarian cancer, according to findings from the phase 2 KGOG 3046.

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors

April 13th 2022

The addition of SOT101, an interleukin-2/IL-15 Rβγ superagonist, to Pembrolizumab generated a clinical benefit and encouraging safety data in patients with advanced solid tumors.

Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC

April 13th 2022

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

FDA Authorizes IND Application for 177Lu-rhPSMA-10.1 for Metastatic Castration-Resistant Prostate Cancer

April 13th 2022

The FDA has cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer.

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13th 2022

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

TTX-030 Plus Budigalimab/mFOLFOX6 Induces Responses in PD-L1–Low Advanced Gastric/GEJ Cancer

April 12th 2022

The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.

Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma

April 12th 2022

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma

April 12th 2022

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

MEDI5752 Demonstrates Intriguing Activity in Advanced Solid Tumors

April 12th 2022

MEDI5752 treatment led to a dose-dependent increase in peripheral T-cell proliferation and encouraging antitumor activity in patients with advanced solid tumors.

Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors

April 12th 2022

The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.

FDA Places Partial Clinical Hold on TakeAim Lymphoma Study Evaluating Emavusertib in B-cell Malignancies

April 12th 2022

The FDA has placed a partial clinical hold on the open-label, dose-escalating phase 1/2 TakeAim Lymphoma study investigating the safety and efficacy of emavusertib in patients with relapsed or refractory B-cell malignancies.

ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma

April 12th 2022

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL

April 12th 2022

The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors

April 11th 2022

The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.

Pembrolizumab Plus Chemotherapy Elicits Meaningful pCR for Gastric, GEJ Adenocarcinoma

April 11th 2022

Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Pepinemab Plus Pembrolizumab Promotes Antitumor Activity in Recurrent/Metastatic Head and Neck Cancer

April 11th 2022

The combination of pepinemab and pembrolizumab elicited encouraging responses and tolerability as frontline therapy in patients with recurrent or metastatic head and neck cancer.

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11th 2022

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

Nivolumab/Ipilimumab Produces Promising ORR in Advanced tTMB- and bTMB-High Solid Tumors

April 11th 2022

The dual immunotherapy combination of nivolumab and ipilimumab elicited encouraging and durable responses with acceptable safety in patients with advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies, meeting the primary end points of the phase 2 CheckMate-848 trial.

Elimusertib Elicits Responses in Solid Tumors With ATM Alterations and BRCA Mutations

April 11th 2022

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.